A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
A phase 1/2 trial of Puxitatug samrotecan, Rilvegostomig, Saruparib in ovarian cancer and endometrial cancer, run by AstraZeneca, now recruiting.
Overview
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies is a phase 1/2 interventional study registered as NCT05123482 by AstraZeneca, with 460 participants planned, started 2021-10-18 and due to reach its primary completion in 2027-09-29. Interventions recorded: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574. Conditions listed: Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Shares Palacaparib, Saruparib, Endometrial cancer, AstraZeneca.
- TrialPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Shares Puxitatug samrotecan, Endometrial cancer, AstraZeneca.
- TrialPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer.
- TrialStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Shares Saruparib, AstraZeneca, Ovarian cancer, Small-cell lung cancer.
- TrialA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.